Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis

Clinical and Experimental Immunology

Volumn 163, Issue 2, 2011, Pages 147-156

  Stinton, L M ^a   Swain, M ^a   Myers, R P ^a   Shaheen, A A ^a   Fritzler, M J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Autoantibodies; GW bodies; Primary biliary cirrhosis; RNA interference

Indexed keywords

3E BPO ANTIGEN; AUTOANTIBODY; AUTOANTIGEN; GE1 ANTIGEN; GLYCINE; GP210 ANTIGEN; GRASP 1 ANTIGEN; GW1 ANTIGEN; GW182 ANTIGEN; GW2 ANTIGEN; GW3 ANTIGEN; LIVER KIDNEY MICROSOMAL 1 ANTIGEN; MITOCHONDRIAL ANTIGEN PYRUVATE DEHYDROGENASE COMPLEX; MITOCHONDRION ANTIBODY; PROMYELOCYTIC LEUKAEMIA CELL ANTIGEN; RNA ASSOCIATED PROTEIN 55 ANTIGEN; SP100 ANTIGEN; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADDRESSABLE LASER BEAD IMMUNOASSAY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; IMMUNOASSAY; LINE IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RNA PROCESSING;

ADULT; AGED; ANTIGENS, NUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; CYTOPLASMIC STRUCTURES; FEMALE; HUMANS; KETOGLUTARATE DEHYDROGENASE COMPLEX; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; PROTEINS; PYRUVATE DEHYDROGENASE COMPLEX; RETROSPECTIVE STUDIES; RIBONUCLEOPROTEINS; RNA-BINDING PROTEINS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 78650845479     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04288.x     Document Type: Article

References (69)

1. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009; 50:291-308.
2. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31:1005-13.
3. Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008; 12:261-76.
4. Worman HJ, Courvalin JC. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2003; 2:211-17.
5. Bloch DB, Yu JH, Yang WH et al. The cytoplasmic dot staining pattern is detected in a subgroup of patients with primary biliary cirrhosis. J Rheumatol 2005; 32:477-83.
6. Bhanji RA, Eystathioy T, Chan EK, Bloch DB, Fritzler MJ. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 2007; 125:247-56.
7. Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell 2002; 13:1338-51.
8. Stinton LM, Selak S, Fritzler MJ. Identification of GRASP-1 as a novel 97 kDa autoantigen localized to endosomes. Clin Immunol 2005; 116:108-17.
9. Yang WH, Bloch DB. Probing the mRNA processing body using protein macroarrays and 'autoantigenomics'. RNA 2007; 13:704-12.
10. Nakamura M, Shimizu-Yoshida Y, Takii Y et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005; 42:386-92.
11. Myers RP, Shaheen AA, Fong A et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009; 50:1884-92.
12. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
13. Vergani D, Alvarez F, Bianchi FB et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41:677-83.
14. Fritzler MJ. Autoantibody testing: procedures and significance in systemic rheumatic diseases. Methods Achiev Exp Pathol 1986; 12:224-60.
15. Smeenk R, Hylkema M. Detection of antibodies to DNA: a technical assessment. Mol Biol Rep 1992; 17:71-9.
16. Eystathioy T, Chan EK, Mahler M, Luft LM, Fritzler ML, Fritzler MJ. A panel of monoclonal antibodies to cytoplasmic GW bodies and the mRNA binding protein GW182. Hybrid Hybridomics 2003; 22:79-86.
17. Mahler M, Kessenbrock K, Raats J, Williams R, Fritzler MJ, Bluthner M. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med 2003; 81:194-204.
18. Eystathioy T, Chan EK, Takeuchi K et al. Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J Mol Med 2003; 81:811-18.
19. Miyachi K, Hosaka H, Nakamura N et al. Anti-p97/VCP antibodies: an autoantibody marker for a subset of primary biliary cirrhosis patients with milder disease? Scand J Immunol 2006; 63:376-82.
20. Selak S, Chan EK, Schoenroth L, Senecal JL, Fritzler MJ. Early endosome antigen. 1: an autoantigen associated with neurological diseases. J Invest Med 1999; 47:311-18.
21. Yu JH, Yang WH, Gulick T, Bloch KD, Bloch DB. Ge-1 is a central component of the mammalian cytoplasmic mRNA processing body. RNA 2005; 11:1795-802.
22. Okada N, Mimori T, Mukai R, Kashiwagi H, Hardin JA. Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol 1987; 138:3219-23.
23. Magsaam J, Gharavi AE, Parnassa AP, Weissbach H, Brot N, Elkon KB. Quantification of lupus anti-ribosome P antibodies using a recombinant P2 fusion protein and determination of the predicted amino acid sequence of the autoantigen in patients' mononuclear cells. Clin Exp Immunol 1989; 76:165-71.
24. Yang WH, Yu JH, Gulick T, Bloch KD, Bloch DB. RNA-associated protein 55 (RAP55) localizes to mRNA processing bodies and stress granules. RNA 2006; 12:547-54.
25. Griffith KJ, Ryan JP, Senecal JL, Fritzler MJ. The cytoplasmic linker protein CLIP-170 is a human autoantigen. Clin Exp Immunol 2002; 127:533-8.
26. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130:715-20.
27. Stinton LM, Eystathioy T, Selak S, Chan EK, Fritzler MJ. Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol 2004; 110:30-44.
28. Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK. Autoimmune targeting of key components of RNA interference. Arthritis Res Ther 2006; 8:R87.
29. Eystathioy T, Jakymiw A, Chan EK, Seraphin B, Cougot N, Fritzler MJ. The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. RNA 2003; 9:1171-3.
30. Laurino CC, Fritzler MJ, Mortara RA, Silva NP, Almeida IC, Andrade LE. Human autoantibodies to diacyl-phosphatidylethanolamine recognize a specific set of discrete cytoplasmic domains. Clin Exp Immunol 2006; 143:572-84.
31. Dong H, Zhang P, Liao D, Huganir RL. Characterization, expression, and distribution of GRIP protein. Ann NY Acad Sci 1999; 868:535-40.
32. Mackay IR. Autoimmunity and primary biliary cirrhosis. Baillières Best Pract Res Clin Gastroenterol 2000; 14:519-33.
33. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25:298-310.
34. Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2:1116-22.
35. Wichmann I, Montes-Cano MA, Respaldiza N et al. Clinical significance of anti-multiple nuclear dots/Sp100 autoantibodies. Scand J Gastroenterol 2003; 38:996-9.
36. Worman HJ. Nuclear envelope protein autoantigens in primary biliary cirrhosis. Hepatol Res 2007; 37 (Suppl. 3):S406-11.
37. Vergani D, Bogdanos DP. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003; 98:241-3.
38. Wesierska-Gadek J, Hohenauer H, Hitchman E, Penner E. Autoantibodies from patients with primary biliary cirrhosis preferentially react with the amino-terminal domain of nuclear pore complex glycoprotein gp210. J Exp Med 1995; 182:1159-62.
39. Bauer A, Habior A. Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis. J Clin Lab Anal 2007; 21:227-31.
40. Itoh S, Ichida T, Yoshida T et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998; 13:257-65.
41. Muratori P, Muratori L, Ferrari R et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98:431-7.
42. Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med 2008; 8:9-15.
43. Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int 2008; 28:233-9.
44. Sternsdorf T, Grotzinger T, Jensen K, Will H. Nuclear dots: actors on many stages. Immunobiology 1997; 198:307-31.
45. Sternsdorf T, Guldner HH, Szostecki C, Grotzinger T, Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol 1995; 42:257-68.
46. Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26:1123-30.
47. Assassi S, Fritzler MJ, Arnett FC et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009; 36:2250-6.
48. Miyachi K, Miyakawa H, Oda M, Horigome T, Fritzler MJ. Primary biliary cirrhosis and autoantibodies. Nihon Rinsho Meneki Gakkai Kaishi 2008; 31:47-55.
49. Rigamonti C, Shand LM, Feudjo M et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55:388-94.
50. Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009; 8:632-7.
51. Granito A, Muratori P, Muratori L et al. Antibodies to SS-A/Ro-52 kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 26:831-8.
52. Miyachi K, Matsushima H, Hankins RW et al. A novel antibody directed against a three-dimensional configuration of a 95-kDa protein in patients with autoimmune hepatic diseases. Scand J Immunol 1998; 47:63-8.
53. Chou MJ, Lee SL, Chen TY, Tsay GJ. Specificity of antinuclear antibodies in primary biliary cirrhosis. Ann Rheum Dis 1995; 54:148-51.
54. Benson GD, Kikuchi K, Miyakawa H, Tanaka A, Watnik MR, Gershwin ME. Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis. Clin Dev Immunol 2004; 11:129-33.
55. Kikuchi K, Hsu W, Hosoya N et al. Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis. Hepatol Res 2009; 39:448-54.
56. Czaja AJ, Nishioka M, Morshed SA, Hachiya T. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994; 107:200-7.
57. Enarson P, Rattner JB, Ou Y, Miyachi K, Horigome T, Fritzler MJ. Autoantigens of the nuclear pore complex. J Mol Med 2004; 82:423-33.
58. Granito A, Muratori P, Muratori L et al. Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther 2006; 24:1575-83.
59. Granito A, Yang WH, Muratori L et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 2010; 105:125-31.
60. Makinen D, Fritzler M, Davis P, Sherlock S. Anticentromere antibodies in primary biliary cirrhosis. Arthritis Rheum 1983; 26:914-17.
61. Fritzler MJ. Autoantibodies in scleroderma. J Dermatol 1993; 20:257-68.
62. Rattner JB. Mapping the mammalian intercellular bridge. [Review]. Cell Motil Cytoskeleton 1992; 23:231-5.
63. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010; 55:2144-61.
64. Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL, Heathcote EJ. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol 2009; 7:1355-60.
65. Miyakawa H, Abe K, Kitazawa E et al. Detection of anti-branched chain 2-oxo acid dehydrogenase complex (BCOADC)-E2 antibody in primary biliary cirrhosis by ELISA using recombinant fusion protein. Autoimmunity 1999; 30:11-20.
66. Agmon-Levin N, Shapira Y, Selmi C et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010; 34:55-8.
67. Tishler M, Alosachie I, Barka N et al. Primary Sjogren's syndrome and primary biliary cirrhosis: differences and similarities in the autoantibody profile. Clin Exp Rheumatol 1995; 13:497-500.
68. Kanzler S, Bozkurt S, Herkel J, Galle PR, Dienes HP, Lohse AW. [Presence of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmune hepatitis (overlap syndrome)]. Dtsch Med Wochenschr 2001; 126:450-6.
69. Tsuchiya K, Kiyosawa K, Imai H, Sodeyama T, Furuta S. Detection of anti-double and anti-single stranded DNA antibodies in chronic liver disease: significance of anti-double stranded DNA antibody in autoimmune hepatitis. J Gastroenterol 1994; 29:152-8.